COVID-19 Resources

The SARS-CoV-2 induced infectious disease (COVID-19) begins as an Acute Respiratory Distress Syndrome (ARDS) with visible symptoms of fever, dry cough, and bilateral pneumonia1. However, for some, it quickly becomes a severe form of pneumosepsis and immune-mediated Multiple Organ Dysfunction Syndrome (MODS) with significantly impaired hepatic, cardiovascular, and renal functions at hospital admission.

Animal models such as ferrets, pigs, monkeys, and transgenic mice are all being used for preclinical research studies for COVID-19 vaccines, monoclonal antibodies, as well as existing and novel antiviral and anti-inflammatory drugs. The inflammation, cardiovascular, renal, and hepatic functions of the animals are being closely monitored throughout these critical studies.

Effectively monitoring both COVID-19 patients and animal models used in preclinical studies is crucial for the road to recovery. Recent studies indicate that the biomarkers shown in the below reagent panel are directly associated with the severity and survival of COVID-192-5.

Alfa Wassermann's COVID-19 Reagent Panel
Reagent Name Item # Kit Size
Alanine Aminotransferase (ALT) SA1052 450 Tests/Kit
Albumin (ALB) SA2001 400 Tests/Kit
Aspartate Aminotransferase (AST) RX1053 200 Tests/Kit
Aspartate Aminotransferase (AST) SA1053 450 Tests/Kit
Creatine Kinase (CK) RX2011 300 Tests/Kit
Creatine Kinase (CK) SA2011 750 Tests/Kit
Creatinine (CREAT) RX1012 186 Tests/Kit
Creatine (CREAT) SA1012 560 Tests/Kit
Ferritin (FERITN) ACI-32 90 Tests/Kit
Lactate Dehydrogenase (LDH) SA3018 330 Tests/Kit
Total Bilirubin (TBILI) SA1008 300 Tests/Kit
   For use on the ACE Axcel® and ACE Alera® Clinical Chemistry Systems.
 


Literature

COVID-19 Follow-up
Monitoring Flyer
COVID-19 Vaccine &
Drug Research Flyer
Comparing COVID-19 mRNA Vaccines
from Pfizer and Moderna


Articles
After the ICU, Many COVID-19 Survivors Face a Long Recovery
Post-intensive-care-unit-syndrome can produce long-term disabilities from muscle wasting, organ damage, brain damage, and PTSD.

As Patients Recover from Coronavirus, Doctors Wonder About Long-Term Health Impacts
The disease attacks many systems within the body - from the lungs and heart to the liver and kidneys.

ChAdOx1 nCoV-19 Vaccination Prevents SARS-CoV-2 Pneumonia in Rhesus Macaques
Non-Human Primates + Mice with Novel Vaccine Treatments

The Chronic Kidney Disease and Acute Kidney Injury Involvement in COVID-19 Pandemic: A Systematic Review and Meta-analysis
There are controversies about whether preexisting chronic kidney disease (CKD) and acute kidney injury complication (AKI) are involved in the COVID-19 pandemic.

Comparative Pathogenesis of COVID-19, MERS, and SARS in a Nonhuman Primate Model
Three human coronaviruses in cynomolgus macaques: severe acute respiratory syndrome-coronavirus (SARS-CoV) (2002), Middle East respiratory syndrome (MERS)-CoV (2012), and SARS-CoV-2 (2019), which causes COVID-19.

Coronavirus: 7 Infection Prevention Best Practices for Healthcare Settings
The novel coronavirus exposes healthcare facilities to several infection risks, including the spread of the virus from asymptomatic people.

The Coronaviruses of Animals and Birds: Their Zoonosis, Vaccines, and Models for SARS-CoV and SARS-CoV2
This review elaborates on the pathogenesis and the developed vaccines of most of the ubiquitous coronavirusí diseases, mainly bovine, dromedary camel, porcine, feline, canine, and avian coronaviruses.

COVID-19 Associated Hospitalization Related to Underlying Medical Conditions
These underlying conditions could put your COVID-19 patients under higher risk of hospitalization.

The Critical Role of Animals in Developing COVID-19 Treatments and Vaccines
Animal studies are essential for advancing COVID-19 related medicine and science.

Discharge Characteristics and Care Transitions of Hospitalized Patients with COVID-19
Due to the unique circumstances of providing transitional care in a pandemic, post-discharge providers must adapt to specific needs and limitations identified for the care of COVID-19 patients.

Emergency Use Authorization for Vaccines to Prevent COVID-19
Download the final guidance document here.

High Odds Severe COVID-19 Can Lead to Kidney Injury or Failure, Medical Studies Reveal
Forty-six percent of patients that were admitted to the hospital with COVID-19 since the beginning of the pandemic had some form of acute kidney injury; of those, 17% required urgent dialysis.

Hyperglycemia Associated with Hospitalization for Severe COVID-19 Infection
Health monitoring of your COVID-19 patients is important not only during the recovery process, but also before they may become infected. Screening your patients for diabetes or prediabetes will help providers know which patients will benefit from making lifestyle changes to lower their risk of a severe COVID-19 infection.

Liver Chemistries in Patients With COVID-19 Who Were Discharged Alive or Died: A Meta-analysis
Although abnormal liver chemistries are linked to a higher risk of COVID-19 related death, liver manifestations may be diverse and even confusing.

Mortality and Renal Outcomes of Patients with Severe COVID-19 Treated in a Provisional Intensive Care Unit
A large number of COVID-19 [patients] will develop acute kidney injury that requires renal replacement therapy (RRT).

An Overview of SARS-CoV-2 and Animal Infection
Experimental studies documented the susceptibility of different animal species to SARS-CoV-2.

Potential Effects of SARS-CoV-2 on the Gastrointestinal Tract and Liver
Research has found that angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 receptor, is strongly expressed in the gastrointestinal tract and liver.

Practice Management Shifts in Priorities and Skills
The COVID-19 pandemic has brought on significant shifts to practice management.


Press Release
May 2020: Alfa Wassermann Diagnostic Technologies Introduces COVID-19 Reagent Panel


Scientific References
1. Zhu N, Zhang D, Wang W. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733

2. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis [published online ahead of print, 2020 Apr 10]. Clin Chem Lab Med. 2020-0369

3. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620?2629

4. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China 2020 Mar 13. JAMA Intern Med. 2020;e200994

5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062